Resumen de Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma

Richard D. Carvajal, Jeffrey A. Sosman, Jorge Fernando Quevedo, Mohammed M. Milhem

• Importance Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in mitogen-activated protein kinase pathway activation.

  Objective To assess the efficacy of selumetinib, a selective, non–adenosine triphosphate competitive inhibitor of MEK1 and MEK2, in uveal melanoma.